Repligen corp stock.
6 hours ago · According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00.
Repligen stock is the IBD Stock Of The Day as Big Pharma's drugmaking partner stays resilient amid the coronavirus pandemic. ... Repligen Corp . Repligen Corp RGEN . $ 104.23 . $0.05 0.05% 42%.Repligen Corp. historical stock charts and prices, analyst ratings, financials, and today’s real-time RGEN stock price. × Funding Description. Security: Description: Exchange: SYMBOL: Common stock, $0.01 par value: EXCHANGEStock Exchange NASDAQ Ticker Symbol RGEN Full Company Profile Financial Performance In 2022, Repligen's revenue was $801.54 million, an increase of …
RGEN SEC Filings - Repligen Corp.- Annual Report, Proxy Statement, Prospectus ... DEFINITIONS The name of the plan is the Second Amended and Restated 2001 Repligen Corporation Stock Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and other. 2008-08-08:Find the latest Repligen Corporation (RGN.F) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Repligen Corporation (NASDAQ:RGEN) Q3 ...
Track Repligen Corp. (RGEN) Stock Price, Quote, latest community messages, chart, news and other stock related information.
Nov 1, 2023 · The stock price rose by $0.27, resulting in a percentage change of +0.61%. While this may seem like a small change, it indicates positive momentum for the company’s stock. Looking ahead, Repligen Corporation is scheduled to release its next financial report on February 15, 2024. Apr 28, 2023 · Repligen Corp’s Stock Price as of Market Close. As of April 28, 2023, 4:00 PM CST, Repligen Corp’s stock price was $151.63. Repligen Corp is up 4.46% from its previous closing price of $145.15. During the last market session, Repligen Corp’s stock traded between $144.20 and $149.36. RGEN - Repligen Corp. - Stock screener for investors and traders, financial visualizations.Third quarter 2023 adjusted gross profit was $59.3 million, a 48% decrease year-over-year and nearly $60 million of lower revenue, and on a lower adjusted gross margin, which was 42% in the third ...... Repligen (RGEN) Frequently Asked Questions. What does Repligen do? Repligen Corp is a global life sciences company. It develops and commercializes innovative ...
Learn more about whether ICU Medical Inc or Repligen Corp is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics. ... AAII Growth Find secular growth stocks poised for outperformance regardless of macroeconomic conditions.
Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock...
RGEN - Repligen Corp. - Stock screener for investors and traders, financial visualizations.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. ... Stocks Rankings for ...Jun 17, 2023 · Allworth Financial LP raised its holdings in Repligen by 62.7% in Q4 and now owns 262 shares of the biotechnology company’s stock valued at $44,000 after adding another 101 shares to its portfolio. Moreover, Achmea Investment Management B.V. entered into a new position with Repligen in the fourth quarter worth $49,000. Dec 2, 2023 · Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis. ... Stock Ideas · Long Ideas · Healthcare. Revisiting Repligen. May 11, 2022 11:31 AM ETRepligen Corporation (RGEN)7 Comments 3 Likes. Another Mountain's ...
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 15.54% in the past year. Currently, Repligen Corp’s price-earnings ratio is 72.6. Repligen Corp’s trailing 12-month revenue is $669.8 million with a 17.3% net profit margin. Year-over-year quarterly sales growth most recently was -29.6%.First quarter 2021 adjusted EPS increased to $0.68 per fully diluted share, compared to $0.32 in the 2020 period, an increase of $0.37, or 116%. Cash and cash equivalents, which are GAAP metrics ...The stock of Repligen Corp. (NASDAQ: RGEN) has increased by 2.04 when compared to last closing price of 157.00. Despite this, the company has experienced a 2.74% gain in its stock price over the last five trading sessions. GlobeNewsWire reported 2023-11-07 that WALTHAM, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) — Repligen …Repligen Corporation acquired Metenova AB for $173 million. Oct. 01: CI Repligen to Acquire Fluid Management Company Metenova Sep. 26: MT Repligen Corporation entered into a definitive agreement to acquire Metenova AB …Feb 24, 2023 · Repligen Corp’s ( RGEN) price is currently down 6.4% so far this month. During the month of February, Repligen Corp’s stock price has reached a high of $200.98 and a low of $164.04. Over the last year, Repligen Corp has hit prices as high as $262.26 and as low as $137.21. Year to date, Repligen Corp’s stock is down 34.51%.
In a report released today, Puneet Souda from SVB Securities maintained a Buy rating on Repligen (RGEN – Research Report), with a price target of $200.00.The company’s shares opened today at ...On November 1, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN had a median target of $190.00, with a high estimate of $210.00 and a low estimate of $148.00. This median estimate represents a significant increase of …
Currently, there are 55.54 million shares of Repligen Corp stock available for purchase. Repligen Corp’s price-earnings (P/E) ratio is currently at 49.4, which is high compared to the Medical Equipment, Supplies & Distribution industry median of 33.1. The price-earnings ratio gauges market expectation of future performance by relating a stock ...Find real-time RGEN - Repligen Corp stock quotes, company profile, news and forecasts from CNN Business.Aug 3, 2023 · Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract ... Repligen Corporation Prices Public Offering of Shares of Common Stock. 6/27/2017. Summary. WALTHAM, Mass., June 27, 2017 (GLOBE NEWSWIRE) - Repligen Corporation ...Shares of bioprocessing technology company Repligen (RGEN 0.98%) were down by 10% on heavy volume as of 12:42 p.m. ET Tuesday. ... Why Repligen Corporation Stock Is Storming Higher Today.Market cap is calculated by taking a company's price per share and multiplying it by the company's total number of shares outstanding. $8.87B. -14.6%. Market Cap / Employee. The market cap of a ... Repligen Corp (RGEN) Stock Shows Promising Performance on September 12, 2023: Analysts Predict 22.75% Increase. On September 12, 2023, Repligen Corp (RGEN) stock showed promising performances based on the information provided by CNN Money. The 13 analysts offering 12-month price forecasts for RGEN have a median …Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …Repligen Corp. analyst ratings, historical stock prices, earnings estimates & actuals. RGEN updated stock price target summary.305.46%. Get the latest Repligen Corp (RGEN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Promising Performance: Repligen Corp (RGEN) Stock Shows Potential for Strong Growth in 2023. On November 1, 2023, Repligen Corp (RGEN) stock had a promising performance based on the information provided. According to the data from CNN Money, the 13 analysts offering 12-month price forecasts for RGEN had a median target …
Summary. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. Repligen Corporation to Present at Upcoming Investor Conferences. Nov. 07. AQ. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03.
Nov 29, 2023 · CI. Repligen Insider Sold Shares Worth $557,328, According to a Recent SEC Filing. Nov. 13. MT. Deutsche Bank Cuts Repligen Price Target to $150 From $165, Maintains Hold Rating. Nov. 07. MT. CORRECTION : RBC Trims Price Target on Regeneron Pharmaceuticals to $837 From $847, Keeps Sector Perform Rating. Nov. 03. Company profile page for Repligen Corp including stock price, company news, press releases, executives, board members, and contact informationGet Repligen Corp (RGEN.A) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Reports first quarter revenue of $182.7 million, with base business growth of 4% as reported and 7% at constant currency Reports first quarter gross margin of 55.2% on both GAAP and adjusted (non-GAAP) basis Closed on acquisition of single-use bag manufacturer FlexBiosys Inc. in April WALTHAM, Mass., May 02, 2023 (GLOBE …Apr 21, 2020 · However, Repligen stock has ramped up nearly 33% in the aftermath, slightly outperforming even a bullish 30% gain for its medical products peers. Janney analyst Paul Knight expects the company to ... Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - …Get the latest Repligen Corporation (RGEN) stock news and headlines to help you in your trading and investing decisions.Oct 9, 2023 · With its stock down 4.8% over the past month, it is easy to disregard Repligen (NASDAQ:RGEN). However, stock prices are usually driven by a company’s financials over the long term, which in this ...
Repligen Corp (NASDAQ:RGEN) 157.02 Delayed Data As of Nov 21 +1.38 / +0.89% Today’s Change 110.45 Today ||| 52-Week Range 200.98 -7.26% Year-to-Date Quote …UPDATE – Repligen Announces Publication of the Company’s 2022 Sustainability Report. November 14, 2023. Our mission is to inspire advances in bioprocessing as a trusted partner in the production of biologic drugs that improve human health worldwide.6 hours ago · According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00. Repligen Corp’s Stock Price as of Market Close. As of April 12, 2023, 4:00 PM CST, Repligen Corp’s stock price was $179.70. Repligen Corp is up 5.46% from its previous closing price of $170.39. During the last market session, Repligen Corp’s stock traded between $166.22 and $171.25.Instagram:https://instagram. 2023 stock picksskf stockmotorcycle insurance quote texasfast food etf 11.55%. Overview. Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis. stanphyl capitalpeople leasing Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.3% in the past year. Currently, Repligen Corp’s price-earnings ratio is 64.0. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. dell earnings release Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen has a market cap of $14.2 billion, while Catalent is valued at $20.2 billion. RGEN shares are down year-to-date through Wednesday, while CTLT has dropped 12%.Dec 1, 2023 · See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.